Your browser doesn't support javascript.
loading
Clinically used broad-spectrum antibiotics compromise inflammatory monocyte-dependent antibacterial defense in the lung.
Dörner, Patrick J; Anandakumar, Harithaa; Röwekamp, Ivo; Fiocca Vernengo, Facundo; Millet Pascual-Leone, Belén; Krzanowski, Marta; Sellmaier, Josua; Brüning, Ulrike; Fritsche-Guenther, Raphaela; Pfannkuch, Lennart; Kurth, Florian; Milek, Miha; Igbokwe, Vanessa; Löber, Ulrike; Gutbier, Birgitt; Holstein, Markus; Heinz, Gitta Anne; Mashreghi, Mir-Farzin; Schulte, Leon N; Klatt, Ann-Brit; Caesar, Sandra; Wienhold, Sandra-Maria; Offermanns, Stefan; Mack, Matthias; Witzenrath, Martin; Jordan, Stefan; Beule, Dieter; Kirwan, Jennifer A; Forslund, Sofia K; Wilck, Nicola; Bartolomaeus, Hendrik; Heimesaat, Markus M; Opitz, Bastian.
Afiliação
  • Dörner PJ; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Anandakumar H; Experimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Röwekamp I; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Fiocca Vernengo F; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
  • Millet Pascual-Leone B; Department of Nephrology and Internal Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Krzanowski M; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Sellmaier J; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Brüning U; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fritsche-Guenther R; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pfannkuch L; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kurth F; Metabolomics Platform, Berlin Institute of Health at Charité, Berlin, Germany.
  • Milek M; Metabolomics Platform, Berlin Institute of Health at Charité, Berlin, Germany.
  • Igbokwe V; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Löber U; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Gutbier B; Core Unit Bioinformatics, Berlin Institute of Health at Charité, Berlin, Germany.
  • Holstein M; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Heinz GA; Experimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Mashreghi MF; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Schulte LN; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
  • Klatt AB; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Caesar S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Wienhold SM; German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany.
  • Offermanns S; German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany.
  • Mack M; Department of Medicine, Institute for Lung Research, Philipps University Marburg, Marburg, Germany.
  • Witzenrath M; German center for lung research (DZL), Marburg, Germany.
  • Jordan S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Beule D; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kirwan JA; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Forslund SK; Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
  • Wilck N; Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
  • Bartolomaeus H; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Heimesaat MM; German center for lung research (DZL), Berlin, Germany.
  • Opitz B; Institute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Nat Commun ; 15(1): 2788, 2024 Mar 30.
Article em En | MEDLINE | ID: mdl-38555356
ABSTRACT
Hospital-acquired pneumonia (HAP) is associated with high mortality and costs, and frequently caused by multidrug-resistant (MDR) bacteria. Although prior antimicrobial therapy is a major risk factor for HAP, the underlying mechanism remains incompletely understood. Here, we demonstrate that antibiotic therapy in hospitalized patients is associated with decreased diversity of the gut microbiome and depletion of short-chain fatty acid (SCFA) producers. Infection experiments with mice transplanted with patient fecal material reveal that these antibiotic-induced microbiota perturbations impair pulmonary defense against MDR Klebsiella pneumoniae. This is dependent on inflammatory monocytes (IMs), whose fatty acid receptor (FFAR)2/3-controlled and phagolysosome-dependent antibacterial activity is compromized in mice transplanted with antibiotic-associated patient microbiota. Collectively, we characterize how clinically relevant antibiotics affect antimicrobial defense in the context of human microbiota, and reveal a critical impairment of IM´s antimicrobial activity. Our study provides additional arguments for the rational use of antibiotics and offers mechanistic insights for the development of novel prophylactic strategies to protect high-risk patients from HAP.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anti-Infecciosos / Antibacterianos Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anti-Infecciosos / Antibacterianos Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article